BackDaewon Pharmaceutical , Ltd. Overview

Daewon Pharmaceutical , Ltd. EBIT

Latest ebit for 003220.KS: $-66B, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$43.43M
↑ 103.42% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$65.55B
↓ 176.64% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Daewon Pharmaceutical , Ltd. (003220.KS) FAQ

Daewon Pharmaceutical , Ltd. (003220.KS) currently reports a EBIT of $-66B as of June 2026. That compares with $86B in the prior-year period — down 176.6% year over year. That is below the sector sector average of $2.4T. Use the charts on this page to explore Daewon Pharmaceutical , Ltd.'s EBIT history and peer comparisons.

Daewon Pharmaceutical , Ltd.'s EBIT decreased from $86B to $-66B — a 176.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Daewon Pharmaceutical , Ltd.'s EBIT of $-66B is lower than the its sector sector average of $2.4T. That is roughly 102.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Daewon Pharmaceutical , Ltd. reported $-66B in EBIT as of June 2026. That compares with $86B in the prior-year period — down 176.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-66B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.4T. From there, open related valuation or income-statement pages for Daewon Pharmaceutical , Ltd., and consider following 003220.KS for alerts when major investors trade the stock.